Search results for "Lymphatic"

showing 10 items of 1179 documents

Transcriptional analysis distinguishes breast implant-associated anaplastic large cell lymphoma from other peripheral T-cell lymphomas

2019

Breast implant-associated anaplastic large cell lymphoma is a new provisional entity in the revised World Health Organization classification of lymphoid malignancies, the pathogenesis and cell of origin of which are still unknown. We performed gene expression profiling of microdissected breast implant-associated anaplastic large cell lymphoma samples and compared their transcriptional profiles with those previously obtained from normal T-cells and other peripheral T-cell lymphomas and validated expression of selected markers by immunohistochemistry. Our results indicate that most breast implant-associated anaplastic large cell lymphomas exhibit an activated CD4+ memory T-cell phenotype, whi…

Adult0301 basic medicinePathologymedicine.medical_specialtyBreast ImplantsCell of originT cell2734BiologyPathology and Forensic Medicine03 medical and health sciences0302 clinical medicineImmunophenotypingMyeloid Cell Differentiationhemic and lymphatic diseasesmedicineHumansRPS10Anaplastic large-cell lymphomaBreast implant-associated anaplastic large cell lymphomabreast implant-associatedanaplastic large cell lymphoma gene expression profiling RPS10Large cellLymphoma T-Cell Peripheralmedicine.diseaseimmunophenotypeLymphomaGene expression profiling030104 developmental biologymedicine.anatomical_structureTranscriptional analysi030220 oncology & carcinogenesisgene expressionLymphoma Large-Cell Anaplasticgene expression; C-Met; lymphoproliferative disorderFemaleC-Metlymphoproliferative disorderTranscriptome
researchProduct

Redefining outcomes in immune TTP: an international working group consensus report

2021

Abstract Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal thrombotic microangiopathy caused by autoantibody-mediated severe deficiency of ADAMTS13. Standardized definitions of response, exacerbation, remission, and relapse were initially proposed in 2003 and modified by the International Working Group for TTP in 2017. These definitions, which have been widely used in clinical practice and research, are based primarily on the platelet count and are benchmarked against the timing of discontinuation of therapeutic plasma exchange (TPE). They do not incorporate ADAMTS13 activity or the temporizing effects on the platelet count of caplacizumab, a novel anti–von W…

Adult0301 basic medicinemedicine.medical_specialtyConsensusThrombotic microangiopathyExacerbation[SDV]Life Sciences [q-bio]ImmunologyThrombotic thrombocytopenic purpuraMEDLINEADAMTS13 Protein030204 cardiovascular system & hematologyBiochemistry03 medical and health sciences0302 clinical medicineFibrinolytic AgentsRecurrencehemic and lymphatic diseasesvon Willebrand FactorHumansMedicineClinical significanceIntensive care medicinePlasma ExchangePurpura Thrombotic ThrombocytopenicPlatelet Countbusiness.industryDisease ManagementCell BiologyHematologySingle-Domain Antibodiesmedicine.diseaseADAMTS133. Good healthDiscontinuationTreatment Outcome030104 developmental biologyFemaleCaplacizumabbusinessBlood
researchProduct

Can We Define the Risk of Lymph Node Metastasis in Early-Stage Cervical Cancer Patients? A Large-Scale, Retrospective Study

2017

BACKGROUND: Sentinel lymph node (SLN) biopsy has emerged as one of the most appreciated techniques for reducing the rate of complete lymph node dissection (LND) performed in patients with early-stage cervical cancer (ECC). However, its performances are still a matter of debate and, to improve them, international guidelines recommend performing at least unilateral LND in case of SLN mapping. In a prior study, we identified a group of patients without evidence of lymph node metastasis (LNM). Our objective is to define a precise risk of LNM for each ECC patient in order to significantly tailor surgery for ECC. METHODS: Clinical and pathological data of ECC patients were retrospectively collect…

AdultAdenocarcinoma; Adult; Aged; Aged 80 and over; Carcinoma Squamous Cell; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Prognosis; Retrospective Studies; Risk Factors; Survival Rate; Uterine Cervical Neoplasms; Young Adult; Lymph Node Excision; Sentinel Lymph Node Biopsy0301 basic medicinemedicine.medical_specialtySentinel lymph nodeUterine Cervical NeoplasmsAdenocarcinomaLogistic regressionYoung Adult03 medical and health sciences0302 clinical medicineRisk FactorsmedicineHumansStage (cooking)Large-Scale Retrospective Study Sentinel lymph node (SLN) biopsy Lymphadenectomy (LND) early-stage cervical cancer (ECC)Lymph nodeAgedRetrospective StudiesAged 80 and overCervical cancerSentinel Lymph Node Biopsybusiness.industryRetrospective cohort studyMiddle AgedPrognosismedicine.diseaseSurgerySurvival Ratecervical cancer lymph nodes metastasesDissectionExact testSettore MED/40 - GINECOLOGIA E OSTETRICIA030104 developmental biologymedicine.anatomical_structureOncologyLymphatic Metastasis030220 oncology & carcinogenesisSurgery; OncologyCarcinoma Squamous CellLymph Node ExcisionFemaleSurgeryRadiologybusinessFollow-Up StudiesAnnals of Surgical Oncology
researchProduct

Is sentinel lymph node biopsy more accurate than axillary dissection on staging the nodal involvement in breast cancer patients?

2007

Today evaluation of axillary involvement can be routinely performed with the technique of sentinel lymph node biopsy (SLNB). One of the greatest advantages of SLNB is the nearly total absence of local postoperative complications. It is important to understand whether SLNB is better than axillary lymph-node dissection (ALND) for staging axillary nodal involvement. The aim of the study was to evaluate the axillary staging accuracy comparing three different methods: axillary dissection, sentinel node biopsy with the traditional 4-6 sections and sentinel node biopsy with complete analysis of the lymph node. 527 consecutive patients (525 females and 2 males) with invasive breast cancer < or = 3 …

AdultAged 80 and overMaleSentinel Lymph Node Breast CancerAnalysis of VarianceSentinel Lymph Node BiopsyBreast NeoplasmsMiddle AgedMastectomy SegmentalSensitivity and SpecificityBreast Neoplasms MalePredictive Value of TestsLymphatic MetastasisAxillaHumansLymph Node ExcisionFemaleAgedNeoplasm Staging
researchProduct

Clinical Features And Course Of Refractory Anemia With Ring Sideroblasts Associated With Marked Thrombocytosis

2012

Background Refractory anemia with ring sideroblasts associated with marked thrombocytosis was proposed as a provisional entity in the 2001 World Health Organization classification of myeloid neoplasms and also in the 2008 version, but its existence as a single entity is contested. We wish to define the clinical features of this rare myelodysplastic/myeloproliferative neoplasm and to compare its clinical outcome with that of refractory anemia with ring sideroblasts and essential thrombocythemia. Design and Methods We conducted a collaborative retrospective study across Europe. Our database included 200 patients diagnosed with refractory anemia with ring sideroblasts and marked thrombocytosis…

AdultBlood PlateletsMalemedicine.medical_specialtyAdolescentAnemiaAnèmiaRefractory anemia with ringed sideroblastsLower riskGastroenterologyRisk FactorsInternal medicinehemic and lymphatic diseasesmedicineHumansMyeloproliferative neoplasmSurvival analysisAgedRetrospective StudiesTumorsAged 80 and overThrombocytosisThrombocytosisPlatelet CountEssential thrombocythemiabusiness.industryAnemia RefractoryAnemiaHematologyJanus Kinase 2Middle Agedmedicine.diseaseSurvival AnalysisAnemia SideroblasticSurgeryEuropeRefractory anemia with ring sideroblastsMutationFemaleOriginal Articles and Brief ReportsbusinessThrombocythemia Essential
researchProduct

CD1a down-regulation in primary invasive ductal breast carcinoma may predict regional lymph node invasion and patient outcome.

2008

AIMS: CD1a is a molecule belonging to the highly conserved group of CD1 proteins. Its expression in dendritic cells is related to the presentation of tumour-derived glycolipid antigens to T cells and, consequently, the development of a successful antitumour response. The aim was to investigate the presence of CD1a+ cells in both primary tumours and lymph nodes (LN) of a series of 35 invasive ductal carcinomas by both immunohistochemistry and reverse transcription-polymerase chain reaction. METHODS AND RESULTS: CD1a antigen was more expressed in N0 than N1 breast cancer (P < 0.0001) in both primary lesions and LN metastases and correlated positively and significantly with oestrogen (ER) (P =…

AdultCD4-Positive T-LymphocytesCarcinoma Ductal BreastDown-RegulationBreast NeoplasmsDendritic CellsCD8-Positive T-LymphocytesMiddle AgedCD1APrognosisImmunohistochemistryAntigens CD1Gene Expression Regulation NeoplasticReceptors EstrogenPredictive Value of TestsLymphatic MetastasisHumansFemaleReceptors ProgesteroneAged
researchProduct

Multidirectional differentiation in a newly established human epithelioid sarcoma cell line (GRU-1) with co-expression of vimentin, cytokeratins and …

1990

A new permanent cell line (GRU-1) derived from the lymph-node metastasis of a human epithelioid sarcoma was established in tissue culture. Immunohistochemically, the original tumor had exhibited an intriguing potential for multidirectional differentiation with features of mesenchymal, epithelial and neural differentiation, evidenced by the co-expression of vimentin, cytokeratins and neurofilament proteins, respectively. This capability for multidirectional differentiation was fully preserved in the cultured cells. GRU-1 tumor cells proved to be uniformly positive for vimentin and a considerable proportion of the tumor cells exhibited a positive reaction for cytokeratins and neurofilament pr…

AdultCancer ResearchPathologymedicine.medical_specialtyNeurofilamentEpithelioid sarcomaMice NudeVimentinCell LineCytokeratinMiceIntermediate Filament ProteinsNeurofilament ProteinsmedicineTumor Cells CulturedAnimalsHumansVimentinbiologyMesenchymal stem cellSarcomaDNA Neoplasmmedicine.diseaseFlow CytometryImmunohistochemistryGene Expression Regulation NeoplasticMicroscopy ElectronCell Transformation NeoplasticOncologyCell cultureLymphatic Metastasisbiology.proteinSynaptophysinKeratinsFemaleSarcomaNeoplasm TransplantationInternational journal of cancer
researchProduct

Validity of Laparoscopic Staging to Avoid Adjuvant Chemoradiation following Radical Surgery in Patients with Early Cervical Cancer

2012

&lt;b&gt;&lt;i&gt;Purpose:&lt;/i&gt;&lt;/b&gt; To determine the rate of unavoidable adjuvant chemoradiation (RCTX) due to histologic results after radical surgery in patients with early cervical cancer. &lt;b&gt;&lt;i&gt;Patients and Methods:&lt;/i&gt;&lt;/b&gt; Between May 2004 and July 2011, 448 consecutive patients diagnosed with invasive cervical cancer stage IA1 L1 to IIA underwent laparoscopic staging at the Department of Gynecology and Gynecologic Oncology at Charité Berlin. Only in patients without lymph node metastases (n = 394) on frozen section, radical operation was continued either by laparoscopic radical hysterectomy (n = 228) or by radical vaginal trachelectomy (n = 166). The…

AdultCancer Researchmedicine.medical_specialtyAdolescentmedicine.medical_treatmentUterine Cervical NeoplasmsRadical vaginal trachelectomyAdjuvant chemoradiationHysterectomyYoung AdultRisk FactorsEarly cervical cancermedicineHumansRadical hysterectomyProspective StudiesRadical HysterectomyRadical surgeryLaparoscopyProspective cohort studyAgedNeoplasm StagingAged 80 and overCervical cancerHysterectomymedicine.diagnostic_testbusiness.industryGeneral surgeryChemoradiotherapy AdjuvantGeneral MedicineMiddle Agedmedicine.diseaseSettore MED/40 - Ginecologia E OstetriciaSurgeryClinical trialOncologyLymphatic MetastasisAdjuvant chemoradiation; Early cervical cancer; Radical hysterectomyVaginaLymph Node ExcisionFemaleLaparoscopyRisk factorbusinessChemoradiotherapy
researchProduct

A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as …

2005

The sequential doxorubicin → CMF (CMF = cyclophosphamide, methotrexate, fluorouracil) regimen has never been compared to CMF in a randomised trial. The role of adding goserelin and tamoxifen after chemotherapy is unclear. In all, 466 premenopausal node-positive patients were randomised to: (a) CMF × 6 cycles (CMF); (b) doxorubicin × 4 cycles followed by CMF × 6 cycles (A → CMF); (c) CMF × 6 cycles followed by goserelin plus tamoxifen × 2 years (CMF → GT); and (d) doxorubicin × 4 cycles followed by CMF × 6 cycles followed by goserelin plus tamoxifen × 2 years (A → CMF → GT). The study used a 2 × 2 factorial experimental design to assess: (1) the effect of the chemotherapy regimens (CMF vs A …

AdultCancer Researchmedicine.medical_specialtyCyclophosphamidemedicine.medical_treatmentUrologyBreast NeoplasmsDisease-Free SurvivalDrug Administration Schedulebreast cancerchemoendocrine treatmentAntineoplastic Combined Chemotherapy ProtocolsClinical StudiesmedicineAdjuvant therapyHumansDoxorubicinCyclophosphamideanthracyclinesGynecologyChemotherapypremenopausalbusiness.industryGoserelinadjuvant therapyMiddle AgedCombined Modality TherapyTamoxifenRegimenMethotrexateOncologyChemotherapy AdjuvantDoxorubicinFluorouracilLymphatic MetastasisGoserelinFemaleFluorouracilbusinessTamoxifenFollow-Up Studiesmedicine.drugBritish Journal of Cancer
researchProduct

Mobilization of peripheral blood progenitor cells with a combination of cyclophosphamide, r-metHuSCF and filgrastim in patients with breast cancer pr…

2002

The objective of our study was to determine the effect of adding r-metHuSCF to Filgrastim and cyclophosphamide for mobilization of peripheral blood progenitor cells (PBPC), on collection of CD34(+) cells and engraftment after autologous stem cell transplant. Twenty-three patients with previously treated stage II-IV breast cancer received cyclophosphamide (3 g/m(2)), Filgrastim 5 microg/kg daily and r-metHuSCF 20 microg/kg daily. Two PBPC collections were performed on consecutive days starting the day the WBC count was above 7.5 x 10(3)/microl. Collection was performed between days +9 and +12 and the median number of CD34(+) cells collected was 9.9 x 10(6)/kg (1.1-53.1) and 6.6 x 10(6)/kg (1…

AdultCancer Researchmedicine.medical_specialtyFilgrastimPlatelet EngraftmentCyclophosphamidemedicine.medical_treatmentUrologyBreast NeoplasmsFilgrastimTransplantation Autologouschemistry.chemical_compoundInternal medicineGranulocyte Colony-Stimulating FactormedicineHumansNeoplasm MetastasisProgenitor cellCyclophosphamideAgedNeoplasm StagingStem Cell FactorChemotherapybusiness.industryHematologyMiddle AgedHematopoietic Stem CellsHematopoietic Stem Cell MobilizationRecombinant ProteinsNitrogen mustardGranulocyte colony-stimulating factorTransplantationTreatment OutcomeEndocrinologyOncologychemistryLymphatic MetastasisFemalebusinessStem Cell Transplantationmedicine.drugLeukemia
researchProduct